Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use

Chronic kidney disease (CKD) is a common complication of diabetes mellitus. It increases significantly cardiovascular risk and decreases the quality of life. CKD requires treatment, and the treatment paradigm for type 2 diabetes has shifted from a glucose-centric approach towards disease-modifying t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. Sh. Khalimov, G. V. Semikova, Yu. A. Shutova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2024-03-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus chronic kidney disease finerenone nonsteroidal mineralocorticoid receptor antagonist fibrosis
Online Access:	https://www.dia-endojournals.ru/jour/article/view/13113
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD
by: Masayuki Yamanouchi, et al.
Published: (2025-07-01)

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
by: I. S. Khalimov, et al.
Published: (2025-01-01)

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
by: Hongxuan Fan, et al.
Published: (2025-08-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action
by: N. P. Trubitsyna, et al.
Published: (2022-12-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings
by: Cezary Kubuj, et al.
Published: (2025-07-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
by: Fei Y, et al.
Published: (2025-06-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study
by: Fei Y, et al.
Published: (2025-05-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
by: Akira Sezai, et al.
Published: (2025-05-01)

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting
by: Manochehr Amini, et al.
Published: (2025-07-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Current Approaches to Treatment and Protein Intake Management in Pre-Dialysis Chronic Kidney Disease: Impact on Physical Exercise
by: Olga Beata Wieczorek, et al.
Published: (2024-10-01)

Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study
by: Guangting Cong, et al.
Published: (2025-08-01)

Efficacy of finerenone in reducing heart failure outcomes in patients with history of heart failure: A meta-analysis of randomized controlled trials
by: Vikash Jaiswal, et al.
Published: (2024-12-01)

Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

A meta-analysis of the effects of finerenone on cardio-renal outcomes in patients with type 2 diabetes mellitus or chronic kidney disease
by: Liu Jing, et al.
Published: (2025-06-01)

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
by: Jingyi Guo, et al.
Published: (2025-03-01)

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
by: Oliver Schnell, et al.
Published: (2025-05-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial
by: Subha V. Raman, et al.
Published: (2019-10-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
by: Ioannis Bellos, et al.
Published: (2024-12-01)

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01)

Multimodality Imaging in Aldosterone-Induced Cardiomyopathy: Early Detection and Prognostic Implications
by: Francesca Zoccatelli, et al.
Published: (2025-07-01)

To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
by: Jinyu He, et al.
Published: (2025-07-01)